Sign in4 stories
The clinical-stage biopharma can sell up to $500 million in shares through TD Cowen under a prospectus dated August 27, 2026, with an amended sales agreement.
SEC filing
Edwards, a former Arcutis and Incyte dermatology commercial leader, joined Oruka on August 24, 2026 with a base salary, bonus target, equity grants, and a signing bonus.
SEC filing
Oruka says EVERLAST-B is fully enrolled ahead of schedule and lays out a string of upcoming data readouts as it holds $1.1 billion in cash.
SEC filing